New drug cocktail aims to beat back tough blood cancers in young patients

NCT ID NCT07513129

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This early-phase study tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) for teens and young adults aged 12 to 30 whose T-cell acute lymphoblastic leukemia or lymphoma has returned or not responded to prior treatment. The main goal is to check safety and side effects. Up to 18 participants will receive the treatment at MD Anderson Cancer Center.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma Precursor T-Cell Lymphoblastic Leukemia-Lymphoma refractory precursor T-lymphoblastic lymphoma/leukemia T-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

UT MD Anderson
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.